In December 2019, the novel coronavirus disease pandemic (COVID-19) that began in China had infected so far more than 109,217,366 million individuals worldwide and accounted for more than 2,413,912 fatalities. With the dawn of this novel coronavirus (SARS-CoV-2), there was a requirement to select potential therapies that might effectively kill the virus, accelerate the recovery, or decrease the case fatality rate. Besides the currently available antiviral medications for human immunodeficiency virus (HIV) and hepatitis C virus (HCV), the chloroquine/hydroxychloroquine (CQ/HCQ) regimen with or without azithromycin has been repurposed in China and was recommended by the National Health Commission, China in mid-February 2020. By this time, the selection of this regimen was based on its efficacy against the previous SARS-CoV-1 virus and its potential to inhibit viral replication of the SARS-CoV-2 in vitro. There was a shortage of robust clinical proof about the effectiveness of this regimen against the novel SARS-CoV-2. Therefore, extensive research effort has been made by several researchers worldwide to investigate whether this regimen is safe and effective for the management of COVID-19. In this review, we provided a comprehensive overview of the CQ/HCQ regimen, summarizing data from in vitro studies and clinical trials for the protection against or the treatment of SARS-CoV-2. Despite the initial promising results from the in vitro studies and the widespread use of CQ/HCQ in clinical settings during the 1st wave of COVID-19, current data from well-designed randomized controlled trials showed no evidence of benefit from CQ/HCQ supplementation for the treatment or prophylaxis against SARS-CoV-2 infection. Particularly, the two largest randomized controlled trials to date (RECOVERY and WHO SOLIDARITY trials), both confirmed that CQ/HCQ regimen does not provide any clinical benefit for COVID-19 patients. Therefore, we do not recommend the use of this regimen in COVID-19 patients outside the context of clinical trials.

Diseases negatively impact the environment, causing many health risks and the spread of pollution and hazards. A novel coronavirus, severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has led to a recent respiratory syndrome epidemic in humans. In December 2019, the sudden emergence of this new coronavirus and the subsequent severe disease it causes created a serious global health threat and hazards. This is in contrast to the two aforementioned coronaviruses, SARS-CoV-2 (in 2002) and middle east respiratory syndrome coronavirus MERS-CoV (in 2012), which were much more easily contained. The World Health Organization (WHO) dubbed this contagious respiratory disease an “epidemic outbreak” in March 2020. More than 80 companies and research institutions worldwide are working together, in cooperation with many governmental agencies, to develop an effective vaccine. To date, six authorized vaccines have been registered. Up till now, no approved drugs and drug scientists are racing from development to clinical trials to find new drugs for COVID-19. Wild animals, such as snakes, bats, and pangolins are the main sources of coronaviruses, as determined by the sequence homology between MERS-CoV and viruses in these animals. Human infection is caused by inhalation of respiratory droplets. To date, the only available treatment protocol for COVID-19 is based on the prevalent clinical signs. This review aims to summarize the current information regarding the origin, evolution, genomic organization, epidemiology, and molecular and cellular characteristics of SARS-CoV-2 as well as the diagnostic and treatment approaches for COVID-19 and its impact on global health, environment, and economy.

Probiotics, such as active yeasts, are widely used to enhance poultry production and reduce feeding costs. This study aimed to investigate the antioxidant and immune responses of broilers to different concentrations of active Saccharomyces cerevisiae (SC) when supplemented to two types of diets. A total of 216 1-day-old Arbor Acres unsexed chicks were used in a factorial design, involving two feeds (regular- versus low-density diet) and three concentrations of SC (0%, 0.02% and 0.04%). The results revealed that the low-density diet reduced the body weight and production index of broilers. The addition of SC improved the production index more than the control diet. Total antioxidant capacity (TAC), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and eosinophils were significantly higher in response to the regular-density diet than the low-density diet; however, phagocytic activity (PA), lymphocyte and lysozyme activity (LYS) were lower. Saccharomyces cerevisiae reduced ALT, AST, malondialdehyde (MAD) and TAC more than the standard set, but improved packed cell volume (PCV), hemoglobin (Hgb), red blood cells (RBCs), lymphocytes, monocytes, heterophils, phagocytic index (PI) and the immune response to Newcastle disease virus (NDV) and avian influenza (AI). In conclusion, supplementation of a regular- or low-density diet with SC at a concentration of 0.02% or 0.04% improved the antioxidant parameters, immune status and production index of broilers against stress and infectious agents.

The current study aims to assess the effect of non-degraded date pits (NDDP) and degraded date pits (DDP) in broilers’ diets on gut microbiota and growth performance. The degradation of date pits (DP) occurred via the cellulolytic fungus Trichoderma reesei by a solid-state degradation procedure. One-day-old Brazilian broilers were allocated into six dietary groups: (1) maize–soy diet, (2) maize–soy diet with oxytetracycline (20%, 50 g 100 kg−1), (3) maize–soy diet with 5% NDDP, (4) maize–soy diet with 10% NDDP, (5) maize–soy diet with 5% DDP, and (6) maize–soy diet with 10% DDP. At the end of the trial, the total count of bacteria was significantly (p < 0.05) less in broilers fed 10% DDP diet (treatment 6) compared with the control group (treatment 1). In addition, DDP and oxytetracycline control diets have a similar diminishing effect on total bacterial counts and the populations of Salmonella, Campylobacter, Shigella spp., and Escherichia coli. Over 35 days of trial, weight gains were similar among the six dietary groups. Our results showed that DDP and control diets have a similar effect on growth performance. The feed conversion ratio (FCR) was poorer in broilers fed NDDP diets than other treatments. The European Production Efficiency Index (EPEI) was greater with 5% and 10% DDP than those fed NDDP at the same levels, with no significant variance from the control and antibiotic-supplemented diet (treatment 2). Overall, it can be suggested that maintaining 10% of DDP can partly replace dietary maize while also serves as a gut health enhancer and thus a growth promoter in the diet for broilers.

A study was conducted to investigate the impact of degraded date pits (DDP) on the development and morphology of the intestine in broilers. Trichoderma reesei was used to produce the DDP using a solid-state degradation method. One hundred and eighty broilers were divided into six treatments in triplicate groups of 10 chicks each. The dietary treatments were: positive control with corn-soy basal diet, negative control with corn-soy basal diet + 20% oxytetracycline at 0.05%, corn-soy basal diet + 10% DDP, cornsoy basal diet + 0.2% mannan-oligosaccharides (MOS), corn-soy basal diet + 0.2% mannose and corn-soy basal diet + 0.1% mannose for 6 weeks. The results indicate that a 10% DDP diet increased the activities of the pancreatic enzymes, the villus length, and the villus/crypt ratio, and decreased the crypt depth of the intestine. In conclusion, when compared to oxytetracycline and MOS, DDP can be used as a replacement for antibiotic growth promoters for broilers while improving gut development and intestinal health.